Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Canaccord Genuity Downgrades Bioventus to Hold

Canaccord Genuity Downgrades Bioventus to Hold

Canaccord Genuity analyst Kyle Rose downgrades Bioventus (NASDAQ:BVS) from Buy to Hold.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Canaccord Genuity analyst Kyle Rose downgrades Bioventus (NASDAQ:BVS) from Buy to Hold.

Mastercard, American Express And A Tech Stock: CNBC’s ‘Final Trades’

By Avi Kapoor

February 5, 9:46 AM

On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors picked Mastercard Incorporated (NYSE: MA).

APH

Here’s How Much $100 Invested In Micron Technology 15 Years Ago Would Be Worth Today

By Benzinga Insights

November 22, 4:02 PM

Micron Technology (NASDAQ:MU) has outperformed the market over the past 15 years by 6.81% on an annualized basis…

Graham Holdings Q4 EPS $18.80 Misses $18.84 Estimate, Sales $1.06B Beat $1.05B Estimate

By Happy Mohamed

February 24, 9:33 AM

Graham Holdings (NYSE:GHC) reported quarterly earnings of $18.80 per share which missed the analyst consensus estimate of $18.84 by 0.21 percent. This is a 119.88 percent increase over earnings of $8.55 per share from

GHC

Why These 4 Pinterest Analysts Are Happy With Q4 Results

By Priya Nigam

February 7, 1:28 PM

Shares of Pinterest Inc (NYSE: PINS) continued to slide on Tuesday, after the company reported quarterly results. KeyBanc Capital Markets on Pinterest

PINS

Canaccord Genuity Downgrades Bioventus to Hold

Related Posts

Mastercard, American Express And A Tech Stock: CNBC’s ‘Final Trades’

Here’s How Much $100 Invested In Micron Technology 15 Years Ago Would Be Worth Today

Graham Holdings Q4 EPS $18.80 Misses $18.84 Estimate, Sales $1.06B Beat $1.05B Estimate

Why These 4 Pinterest Analysts Are Happy With Q4 Results